Skip to main content
SpringerLink
Log in

Pharmacokinetics of Orally Administered Duloxetine in Children and Adolescents with Major Depressive Disorder

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background

Duloxetine, a selective serotonin (5-hydroxytryptamine) and norepinephrine reuptake inhibitor, has been approved since 2004 for the treatment of adults with major depressive disorder (MDD). It is currently not approved for use in pediatric patients (aged <18 years) with MDD. The clinical development program for duloxetine in the pediatric MDD population, which consisted of three clinical studies, provided extensive data on the safety, tolerability, and pharmacokinetics of duloxetine across a wide dose range in pediatric patients of differing ages, sex, body weights, and sexual maturation.

Objectives

The objectives were to characterize the pharmacokinetics of duloxetine based on population modeling following daily oral administration in children and adolescents aged 7–17 years diagnosed with MDD; to estimate the magnitude of between- and within-patient variability; to identify potential patient factors affecting duloxetine pharmacokinetics, and to compare duloxetine pharmacokinetics in the pediatric population with those characterized in adults.

Methods

The analyses meta-dataset was created from pharmacokinetic and demographic data available from one phase II (open-label) and two phase III (randomized, double-blind) clinical trials of duloxetine in children and adolescents. Patients received 20–120 mg of oral duloxetine once daily. Duloxetine concentrations (a total of 1,581 concentrations) were obtained from 428 patients: 34 % were children (aged 7–11 years) and 66 % were adolescents (aged 12–18 years). Population modeling analyses were performed using nonlinear mixed-effects modeling and the first-order conditional estimation method with interaction. Patient factors were assessed for their potential influence on duloxetine apparent clearance (CL/F) and apparent volume of distribution (V d/F). Duloxetine pharmacokinetic parameters and model-predicted duloxetine concentrations at steady state in the pediatric population were compared with those in adults.

Results

Duloxetine pharmacokinetics in pediatric patients was described by a one-compartmental model. Typical values of CL/F, V d/F, and half-life (t 1/2) at 60 mg/day of duloxetine were 79.7 L/h, 1,200 L, and 10.4 h, respectively. The between-patient variability in CL/F and V d/F was 68 and 87 %, respectively, while within-patient variability was 57 % (proportional error) and 2.04 ng/mL (additive error). Body surface area (BSA), dose, and race had a statistically significant effect on duloxetine pharmacokinetics. With a 2.2-fold increase in BSA, the CL/F increased about twofold. A sixfold increase in dose (20 to 120 mg) decreased CL/F by 32 %. In American Indian patients, V d/F was 131 % higher than the other races combined. Age, sex, body mass index, serum creatinine, cytochrome P450 2D6 predicted phenotype, and menarche status did not have a statistically significant effect. Estimates of CL/F and V d/F were higher in the pediatric population than in adults; subsequently, the average steady-state duloxetine concentration was approximately 30 % lower in the pediatric population than in adults.

Conclusions

Duloxetine pharmacokinetics was similar in children and adolescents with MDD. The statistically significant effects of dose, BSA, and race on duloxetine pharmacokinetics in pediatric patients did not appear to be clinically meaningful. At a given dose, the typical steady-state duloxetine concentrations in the pediatric population were lower than in adults, and the distribution of steady-state duloxetine concentrations in pediatric patients were typically in the lower range of concentrations in adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Shaffer D, Fisher P, Dulcan MK, et al. The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA Study. Methods for the Epidemiology of Child and Adolescent Mental Disorders Study. J Am Acad Child Adolesc Psychiatry. 1996;35(7):865–77.

    Article  CAS  PubMed  Google Scholar 

  2. Hammerness PG, Vivas FM, Gellar DA. Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence. J Pediatr. 2006;148(2):158–65.

    Article  CAS  PubMed  Google Scholar 

  3. Prozac® (fluoxetine hydrochloride tablets) full prescribing information. Prozac website [online]. Available at http://www.fluoxetine60.com/prescribing-information.php. Updated 2011. Accessed Jun 2011.

  4. Lexapro® (escitalopram oxalate tablets) full prescribing information. Forest Laboratories website [online]. Available at http://www.frx.com/products/lexapro.aspx. Updated 2011. Accessed May 2011.

  5. Atuah KN, Hughes D, Pirmohamed M. Clinical pharmacology: special safety considerations in drug development and pharmacovigilance. Drug Saf. 2004;27(8):535–54.

    Article  CAS  PubMed  Google Scholar 

  6. Findling RL, McNamara NK, Stansbrey RJ, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol. 2006;16(1–2):131–45.

    Article  PubMed  Google Scholar 

  7. Cymbalta® (duloxetine hydrochloride capsules) full prescribing information. Cymbalta website [online]. Available at http://www.cymbalta.com/Pages/index.aspx. Updated 2012. Accessed Nov 2012.

  8. Prakash A, Lobo E, Kratochvil CJ, et al. An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. J Child Adolesc Psychopharmacol. 2012;22(1):48–55.

    Article  CAS  PubMed  Google Scholar 

  9. Emslie G, Prakash A, Zhang Q, et al. A double-blind, efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2014;24(4):170–9.

  10. Atkinson SD, Prakash A, Zhang Q, et al. A double-blind, efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2014;24(4):180–9.

  11. Beal S, Sheiner LB, Boeckmann A, et al. NONMEM user’s guide. (1989–2011). Ellicott City (MD): Icon Development Solutions; 2011.

  12. Lobo ED, Quinlan T, O’Brien L, et al. Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Clin Pharmacokinet. 2009;48(3):189–97.

    Article  CAS  PubMed  Google Scholar 

  13. O’Brien L, Hewitt R, Heathman M, et al. Challenging the robustness of a population pharmacokinetic model obtained from a phase III raloxifene study [abstract no. 3548.] American Association of Pharmaceutical Sciences Annual Meeting; 1998 Nov 15–19; San Francisco (CA).

  14. Alderman J, Wolkow R, Chung M, et al. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry. 1998;37(4):386–94.

    Article  CAS  PubMed  Google Scholar 

  15. Findling RL, Reed MD, Myers C, et al. Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38(8):952–9.

    Article  CAS  PubMed  Google Scholar 

  16. Wilens TE, Cohen L, Biederman J, et al. Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol. 2002;22(6):568–75.

    Article  CAS  PubMed  Google Scholar 

  17. Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet. 2008;47(3):191–202.

    Article  CAS  PubMed  Google Scholar 

  18. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73(3):170–7.

    Article  CAS  PubMed  Google Scholar 

  19. Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol. 2003;17(3):281–99.

    Article  CAS  PubMed  Google Scholar 

  20. Zoloft® (sertraline hydrochloride tablets and oral concentrate) full prescribing information. Zoloft website [online]. Available at http://www.zoloft.com/. Updated 2012. Accessed May 2012.

  21. Paxil® (paroxetine hydrochloride tablets and oral suspension) full prescribing information. Paxil website [online]. Available at http://us.gsk.com/products/assets/us_paxil.pdf. Updated 2011. Accessed July 2011.

Download references

Acknowledgments

This work was funded by Eli Lilly and Company, Indianapolis, IN, USA. All authors are employees of Eli Lilly and Company and own stock options in Eli Lilly and Company. Assistance with manuscript preparation was provided by Susan LaGreca, INC Research, Raleigh, NC, USA.

The authors thank the principal investigators and their clinical staff. The authors also thank the many patients and their families who generously agreed to participate in this clinical trial and the clinical operations staff and statistical analysts of the duloxetine antidepressant team for their excellent implementation of the trial.

Author information

Authors and Affiliations

  1. Lilly Research Laboratories, Eli Lilly and Company, DC 0724, Indianapolis, IN, 46285-0724, USA

    Evelyn D. Lobo, Tonya Quinlan & Apurva Prakash

Authors
  1. Evelyn D. Lobo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tonya Quinlan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Apurva Prakash
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Evelyn D. Lobo.

Additional information

Clinical trial registration numbers: F1J-MC-HMFN: NCT00529789; F1J-MC-HMCK: NCT00849901; F1J-MC-HMCL: NCT00849693.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lobo, E.D., Quinlan, T. & Prakash, A. Pharmacokinetics of Orally Administered Duloxetine in Children and Adolescents with Major Depressive Disorder. Clin Pharmacokinet 53, 731–740 (2014). https://doi.org/10.1007/s40262-014-0149-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-014-0149-y

Keywords

Search

Navigation